Rubella is an infectious disease caused by rubella virus (RUBV) which is highly contagious. As a pioneering company in infectious disease therapy, we specialize in the development of comprehensive rubella vaccine and therapeutic solutions.
Overview of Rubella
Rubella is also known as German measles or three days measles. It is common viral disease occurring as a result of infection and is transmitted respiratory droplets and through close contact with the infected individual. Rubella has mild symptoms but can cause serious problems for an unborn child. A pregnant woman who contracts rubella particularly in the first trimester may suffer miscarriages or give birth to a stillborn child, or the newborn may suffer from congenital rubella syndrome. The rubella virus is classified under the Matonaviridae family and is an enveloped, positive sense, single-stranded RNA virus.
Fig.1 Model of the RUBV life cycle. (Das P. K., et al., 2021)
Vaccine Development for Rubella
Live Attenuated Vaccines
The live attenuated vaccine has been the most radical accomplishment for rubella prevention. The RA27/3 rubella vaccine is the most used formulation internationally, developed in the 1960s. It was developed from the rubella virus which was isolated then weakened through attenuation so as to boost safety and still provide an immune response. This vaccine has been proven to bestow long term immunity and decrease rubella and CRS.
Combination Vaccines
Rubella vaccines are included in combination vaccines and are administrated along with other vaccines, for example, the Measles Mumps Rubella (MMR) vaccine. The MMR vaccine has helped in decreasing the incidence of both measles as well as mumps while concurrently lowering rubella infections. Public health measures have combined these vaccines so that more people are reached and the impact of these diseases is lessened.
Therapeutics Development for Rubella
As of now, Rubella therapeutic is largely limited to supportive therapeutic as there exists no known specific antiviral treatment. Nevertheless, work is being carried out for the development of rubella specific therapeutics.
| Rubella-Specific Immunoglobulin |
To be prescribed in case of exposure to rubella, it aids in lessening the savagery of the disease. |
| Corticosteroids or Immunoglobulin |
May be considered in treating rubella's post-infectious Encephalitis. |
Our Services
We specialize in vaccine therapy and alongwith rubella vaccination, we advance in developing therapeutic strategies. In vaccine development, we emphasize on strain selection and attenuation for safety, formulation for stability, and conduct preclinical studies to endorse the effectiveness of novel vaccines. In regards to therapeutics, we utilize AI for target Identification, employ high-throughput methods for drug screening followed by rigorous preclinical research to establish effectiveness and safety of potential rubella therapeutics.
Disease Models
- Rubella Virus (RV) Infection Mouse Models: BALB/c mice intramuscular injection
- Rubella Virus (RV) Infection Rat Models
- Customized Animal Model Development
Comprehensive vaccine and therapeutics development services are delivered with a focus on addressing rubella. Our expertise encompasses various stages of product development, from drug discovery to preclinical research. If you are interested in our services, please feel free to contact us.
References
- Das, Pratyush Kumar, and Margaret Kielian. "Molecular and structural insights into the life cycle of rubella virus." Journal of virology 95.10 (2021): 10-1128.
- Winter, Amy K., and William J. Moss. "Rubella." The Lancet 399.10332 (2022): 1336-1346.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
